137 related articles for article (PubMed ID: 15293148)
1. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
Itoh Y; Okanoue T
J Gastroenterol; 2004 Jul; 39(7):704-5. PubMed ID: 15293148
[No Abstract] [Full Text] [Related]
2. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
Kasahara A
J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
[No Abstract] [Full Text] [Related]
3. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
Takaki S; Tsubota A; Hosaka T; Akuta N; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Jul; 39(7):668-73. PubMed ID: 15293138
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
Demelia L; Civolani A; Murgia D; Murru A; Sorbello O; Rizzetto M
J Hepatol; 2007 Jan; 46(1):171-3. PubMed ID: 17107736
[No Abstract] [Full Text] [Related]
5. Factors contributing to ribavirin-induced anemia.
Nomura H; Tanimoto H; Kajiwara E; Shimono J; Maruyama T; Yamashita N; Nagano M; Higashi M; Mukai T; Matsui Y; Hayashi J; Kashiwagi S; Ishibashi H
J Gastroenterol Hepatol; 2004 Nov; 19(11):1312-7. PubMed ID: 15482540
[TBL] [Abstract][Full Text] [Related]
6. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
J Gastroenterol; 2004 Nov; 39(11):1090-4. PubMed ID: 15580403
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
Gournay J; Richou C
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B60-75. PubMed ID: 12180310
[No Abstract] [Full Text] [Related]
8. Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
Balestrieri C; Serra G; Cauli C; Chessa L; Balestrieri A; Farci P
Blood; 2006 Apr; 107(8):3409-10. PubMed ID: 16597599
[No Abstract] [Full Text] [Related]
9. Cutaneous reactions to interferon and ribavirin.
Chamberlain AJ; Poon E
Intern Med J; 2004 Aug; 34(8):519. PubMed ID: 15317557
[No Abstract] [Full Text] [Related]
10. [Incidence of haemolytic anaemia during combination therapy of chronic hepatitis C with interferon alpha-2b and ribavirin].
Adamek A; Adamek J; Juszczyk J
Pol Merkur Lekarski; 2004 Nov; 17(101):443-5. PubMed ID: 15754628
[TBL] [Abstract][Full Text] [Related]
11. [Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
Nishino R; Ikeda N; Unoura M
Nihon Shokakibyo Gakkai Zasshi; 2011 Sep; 108(9):1571-8. PubMed ID: 21891998
[TBL] [Abstract][Full Text] [Related]
12. Should ribavirin be used to treat hepatitis C in dialysis patients?
Carrion AF; Fabrizi F; Martin P
Semin Dial; 2011; 24(3):272-4. PubMed ID: 21480995
[TBL] [Abstract][Full Text] [Related]
13. Leucopenia is a side effect of combination therapy for hepatitis C infection.
Russo F; Bacosi M; Miglioresi L; Ricci GL
Am J Gastroenterol; 2000 Apr; 95(4):1100-1. PubMed ID: 10763981
[No Abstract] [Full Text] [Related]
14. Interferon plus ribavirin: a cautionary note.
Macedo G; Ribeiro T
Am J Gastroenterol; 1999 Oct; 94(10):3087-8. PubMed ID: 10520894
[No Abstract] [Full Text] [Related]
15. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
Bräu N
J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
[TBL] [Abstract][Full Text] [Related]
16. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Nishiofuku M; Tsujimoto T; Matsumura Y; Toyohara M; Yoshiji H; Yamao J; Fukui H; Yoshikawa M
Intern Med; 2006; 45(7):483-4. PubMed ID: 16679707
[No Abstract] [Full Text] [Related]
17. The uncertain natural history of thyrotoxic patients treated with combination interferon alfa-2beta and ribavirin.
Tran HA
Arch Intern Med; 2005 May; 165(9):1072; author reply 1072-3. PubMed ID: 15883255
[No Abstract] [Full Text] [Related]
18. [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].
Savoye G; Goria O; Herve S; Riachi G; Noblesse I; Bastien L; Courville P; Lerebours E
Gastroenterol Clin Biol; 2000; 24(6-7):679. PubMed ID: 10962394
[No Abstract] [Full Text] [Related]
19. [Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C].
Han KH; Yoon YH
Korean J Hepatol; 2004 Jun; 10(2):81-7. PubMed ID: 15218341
[No Abstract] [Full Text] [Related]
20. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
Gentile I; Viola C; Reynaud L; Borrelli F; Cerini R; Ciampi R; Piazza M; Borgia G
J Interferon Cytokine Res; 2005 May; 25(5):283-5. PubMed ID: 15871666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
